NEW YORK, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Progyny, a leading digital healthcare company, today announced it will rebrand its direct-to-consumer products under the parent company. The rebrand will also include the launch of a new website and new features available for patients looking to learn more about their fertility options and journey.
Progyny’s direct-to-consumer products, EggBanxx will now be Progyny Egg Freezing, and IVFAdvantage, will now be Progyny IVF. Progyny Egg Freezing will continue to provide information and a plan for women interested in preserving their fertility through egg freezing. Progyny IVF will continue to provide a no-restriction in vitro fertilization (IVF) plan and be accessible to any individual or couple who might be struggling to conceive. Both products will provide individuals with exclusive pricing, financing and support from the company’s patient care advocates and best in care treatment from its national network of elite fertility doctors and clinics.
The new website will feature Progyny’s clinical and proprietary software technology, EEVA® (early embryo viability assessment). EEVA is the first and only FDA-cleared, non-invasive embryo assessment tool for IVF patients. Over the next several quarters, Progyny is planning to introduce additional software tools to help improve outcomes and provide more choice for patients.
“Our dedication and investment in proprietary, clinical technology is part of our mission to help anyone who wants to have a baby, have a healthy one. We want to give our patients and doctors the confidence of knowing they’ve made the right choice,” said Gina Bartasi, CEO of Progyny.
The launch of the new website aims to make it easier for consumers and employer members with Progyny fertility benefits to navigate through their options, select a doctor, and better understand their best course of treatment. The website will allow users to request appointment times with top experts across the country. In addition, similar to the Progyny App, the website will provide users with success rates, patient ratings, pricing, the ability to speak with a patient care advocate for support, and offer education through curated content, videos, and FAQs.
“By bringing all of our products under one brand, we aim for Progyny to be a household name and the go to source for all fertility solutions. This rebrand is just the first step,” added Bartasi.
“We are excited for this new phase and look to roll out new features including the ability for members to easily access their benefit claims information, a fertility calculator and IVF predictor tool,” said George Nassef, EVP of Operations and CTO.
The new features will continue to be released by the end of this year and into 2017.
For more information and to visit the new website please visit, www.progyny.com.
Progyny is a leading digital healthcare company combining data, science and technology to provide the first end-to-end, proactive fertility solution for both large, self-insured employers and today’s informed consumer. Progyny’s SMART™ Cycle plan design comprises best-in-class research and clinical solutions, including its proprietary EEVA® technology, to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. Progyny is privately held and is headquartered in New York, NY, with operations in San Francisco, CA. Please visit www.progyny.com.
Last updated on: 23/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.